Eicosatetraenoic acid, 12-hydroxy- | 68795-05-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Eicosatetraenoic acid, 12-hydroxy-
• 英文别名: (2E,4E,6E,8E)-12-hydroxyicosa-2,4,6,8-tetraenoic acid
• CAS: 68795-05-1
• 化学式: C₂₀H₃₂O₃
• 分子量: 320.5
• InChiKey: TYCYGLFFOSNBLU-ODWCVSANSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  23
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION
  申请人：UNIVERSITY OF MASSACHUSETTS

  公开号：US20200138756A1

  公开（公告）日：2020-05-07

  Disclosed herein are methods and compositions for treating neutrophil-mediated inflammation by targeting, in any combination, the pro-inflammatory MRP2/HXA3 pathway and/or the anti-inflammatory P-gp/endocannabinoid pathway and/or the anti-inflammatory MRP 1/L-AMEND pathway, comprising administering to the subject a therapeutically effective amount of (a) one or more first compound that inhibits the activity and/or level of one or more of multidrug resistance protein 2 (MRP2) and hepoxilin A3 (HXA3) synthase, and/or (b) one or more second compound that increases the level and/or activity of one or more N-acylethanolamines (NAEs), and/or (c) one or more third compound that increases the level and/or activity of multidrug resistance protein 1 (MRP1), wherein the therapeutic amount of the first, second, and third compounds reduces migration of neutrophils into the target tissue.

  本文披露了一种治疗中性粒细胞介导炎症的方法和组合物，通过以任何组合方式靶向抗炎 MRP2/HXA3 途径和/或抗炎 P-gp/内源性大麻素途径和/或抗炎 MRP 1/L-AMEND 途径，包括向受试者施用治疗有效量的（a）抑制一种或多种多药耐药蛋白2（MRP2）和肝过氧化脂酸A3（HXA3）合酶的活性和/或水平的一种或多种第一化合物，和/或（b）增加一种或多种N-乙酰基乙醇胺（NAEs）的水平和/或活性的一种或多种第二化合物，和/或（c）增加一种或多种多药耐药蛋白1（MRP1）的水平和/或活性的一种或多种第三化合物，其中第一、第二和第三化合物的治疗量减少中性粒细胞向目标组织的迁移。
• [EN] 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING HEMOGLOBINOPATHY, THALASSEMIA, SICKLE CELL DISEASE AND OTHER DISORDERS<br/>[FR] 2,3,5-TRIMÉTHYL-6-NONYLCYCLOHEXA-2,5-DIÈNE-1,4-DIONE POUR SUPPRIMER ET TRAITER L'HÉMOGLOBINOPATHIE, LA THALASSÉMIE, LA DRÉPANOCYTOSE ET D'AUTRES TROUBLES
  申请人：PTC THERAPEUTICS INC

  公开号：WO2021077034A1

  公开（公告）日：2021-04-22

  Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of hemoglobinopathy, thalassemia, α-thalassemia, α-thalassemia minima, α-thalassemia minor, β-thalassemia, β-thalassemia minor, β-thalassemia major, β-thalassemia intermedia, δ-thalassemia, sickle-cell disease, and combinations thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: (I) or the hydroquinone form thereof; or a solvate or hydrate thereof.

  本公开涉及治疗或抑制从血红蛋白病、地中海贫血、α-地中海贫血、α-地中海贫血轻度型、α-地中海贫血轻度型、β-地中海贫血、β-地中海贫血轻度型、β-地中海贫血重度型、β-地中海贫血中间型、δ-地中海贫血、镰状细胞病以及这些疾病的组合中选择的紊乱的方法，包括向需要的受试者施用公式(I)的化合物或其氢醌形式的治疗有效量；或其溶剂或水合物。
• PHARMACEUTICAL COMPOSITIONS INCLUDING CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUND
  申请人：Moon Hong Sik

  公开号：US20130131081A1

  公开（公告）日：2013-05-23

  A pharmaceutical composition that includes a carbamoyloxy arylalkanoyl arylpiperazine compound SERUM CHOLESTEROL and effectively prevents or treats diabetic nephropathy, diabetic neuropathy, diabetic vascular complications, hyperlipidemia, coronary artery disease, or inflammation.

  一种包含羰胺氧基芳基丙酰基芳基哌嗪化合物血清胆固醇的制药组合物，有效预防或治疗糖尿病肾病、糖尿病神经病变、糖尿病血管并发症、高脂血症、冠状动脉疾病或炎症。
• Preventing and/or treating cardiovascular disease and/or associated heart failure
  申请人：——

  公开号：US20030203973A1

  公开（公告）日：2003-10-30

  Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.

  提供了一些方法来减少铜的值，例如通过处理、预防或改善组织损伤，例如可能由以下原因引起的组织损伤：（i）心肌疾病（例如心肌病或心肌炎）如特发性心肌病、代谢性心肌病（包括糖尿病性心肌病、酒精性心肌病、药物诱导性心肌病、缺血性心肌病和高血压性心肌病）、（ii）主要血管的动脉粥样硬化性疾病（宏血管疾病）如主动脉、冠状动脉、颈动脉、脑血管动脉、肾动脉、髂动脉、股动脉和腘动脉、（iii）毒性、药物诱导和代谢性（包括小血管的高血压和/或糖尿病性疾病（微血管疾病）如视网膜小动脉、肾小动脉、神经血管、心脏小动脉以及与眼睛、肾脏、心脏以及中枢和外周神经系统相关的毛细血管床、（iv）主要血管的动脉粥样硬化斑块破裂如主动脉、冠状动脉、颈动脉、脑血管动脉、肾动脉、髂动脉、股动脉和腘动脉，（v）糖尿病或糖尿病并发症。
• [EN] INHIBITORS OF HUMAN 12/15-LIPOXYGENASE<br/>[FR] INHIBITEURS DE LA 12/15-LIPOXYGÉNASE- HUMAINE
  申请人：GEN HOSPITAL CORP

  公开号：WO2015027146A1

  公开（公告）日：2015-02-26

  A systematic screening has revealed a family of compounds that exhibit inhibitory effects on 12/15-lipoxygenase. Accordingly, the present invention relates to the use of these compounds for the inhibition of 12/15-lipoxygenase and for the treatment of a condition involving 12/15-lipoxygenase. Exemplary conditions include, but are not limited to, stroke, periventricular leukomalacia, cardiac arrest with resuscitation, atherosclerosis, Parkinson's disease, Alzheimer's disease, and breast cancer.

  一项系统性筛选发现了一类化合物，具有对12/15-脂氧合酶的抑制作用。因此，本发明涉及使用这些化合物来抑制12/15-脂氧合酶并治疗涉及12/15-脂氧合酶的疾病。典型的疾病包括但不限于中风、脑室周围白质损伤、心脏骤停复苏、动脉硬化、帕金森病、阿尔茨海默病和乳腺癌。